{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056413","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.398839+00:00","generated_at":"2026-06-28T09:03:50.204742+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eledon Q3 net loss of $9.8M ($0.66/sh); pipeline progress in ALS, IgAN, transplant","bullets":["Net loss of $9.8M for Q3 2021 vs $6.1M; R&D expenses surged to $7.7M from $0.6M.","Cash of $94.0M as of Sept 30, 2021; company funded into 2023.","Phase 2 ALS study nearing full enrollment; topline data expected 1H 2022.","IND clearance for AT-1501 in islet cell transplantation; kidney and IgAN trials expected Q4 2021 start.","Research collaboration with CareDx for renal transplant biomarkers and predictive algorithms."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056413","json":"https://secwatch.observer/filing/0001564590-21-056413.json","markdown":"https://secwatch.observer/filing/0001564590-21-056413.md","text":"https://secwatch.observer/filing/0001564590-21-056413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000156459021056413/0001564590-21-056413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000156459021056413/eldn-8k_20211111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:03:50.204742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}